CABOMETYX® (cabozantinib) and Renal Cell Carcinoma Guidelines

Cabometyx and the ESMO RCC Guidelines

The only TKI to be given a ‘Grade A’ recommendation in patients who have received prior TKI therapy [I,A] and treatment-naïve patients (intermediate-risk) [II,A]

For more info about the latest ESMO clinical practice guidelines on the diagnosis, treatment and follow-up of renal cell carcinoma:

Cabometyx and the EAU RCC Guidelines

Read about the 2019 update of the EAU guidelines on renal cell carcinoma.

Cabometyx and the NCCN RCC Guidelines

The only TKI to be designated as “preferred” in treatment-naïve patients (intermediate-, poor-risk) and those who have received prior therapy

For more info about NCCN clinical practice guidelines on renal cell carcinoma: